Meme Kanserinde tümör baskılayıcı gen adayı olarak DNAJC25

DNAJC25 geni HSP40 (DNAJ) ailesinin bir üyesidir ve hepatoselüler karsinomada tümör baskılayıcı gen olarak önerilmiş tir. Bu çalışmanın amacı, meme kanserinde DNAJC25 geninin ifadesini, genetik/epigenetik değişimlerini ve prognostikönemini analiz etmekdir. DNAJC25 mRNA ifadesi meme kanseri hücre hatlarında farklılık göstermektedir. Tümörijenik ol mayan meme epitel hücre hattına (MCF 10A) göre, DNAJC25 transkript seviyesi BT-20 ve ZR-75-1 hücre hatlarında upregüleolurken, MDA-MB-231 hücre hattında downregüle olmuştur (P

DNAJC25 as a tumor suppressor candidate gene in breast cancer

DNAJC25 gene is a member of the HSP40 (DNAJ) family, and it was suggested as a tumor suppressor gene in hepatocellular carcinoma. The aim of this study was to analyze the expression, genetic/epigenetic alterations, and prognostic value of the DNAJC25 gene in breast cancer. DNAJC25 transcript levels are upregulated in BT-20 and ZR-75-1 cell lines and downregulated in MDA-MB-231 cell line compared to the non-tumorigenic mammary epithelial cell line (MCF 10A) (P< 0.05). According to UALCAN in-silico tool, clinical breast cancer samples show significantly reduced levels of DNAJC25 mRNA relative to the normal samples (P=1.47e-02). The Kaplan–Meier plotter tool shows that high DNAJC25 expression is favorable for post-progression survival in breast cancer (P=0.0035). Point mutations or copy number variations of DNAJC25 are uncommon in clinical breast cancer samples. Combined bisulfite restriction analysis (COBRA) results showed that DNAJC25promoter is not methylated in breast cell lines. Promoter hypomethylation was also observed in normal and tumor clinical samples (Beta-value

PDF

___

1. F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, and A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA. Cancer J. Clin., 68 (2018) 394- 424.
2. A.A. Khalil, N.F. Kabapy, S. F. Deraz, and C. Smith, Heat shock proteins in oncology: Diagnostic biomarkers or therapeutic targets?, Biochim. Biophys. Acta - Rev. Cancer, 1816 (2011) 89-104.
3. J.N. Sterrenberg, G.L. Blatch, and A.L. Edkins, Human DNAJ in cancer and stem cells, Cancer Lett., 312 (2011) 129-142.
4. T. Liu, W. Jiang, D. Han, L. Yu, DNAJC25 is downregulated in hepatocellular carcinoma and is a novel tumor suppressor gene, Oncol. Lett., 4 (2012) 1274-1280.
5. M. Uhlen, L. Fagerberg, B.M. Hallstrom et al., Tissue-based map of the human proteome, Science, 347 (2015) 1260419.
6. K.J. Livak and T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods, 25 (2001) 402-408.
7. B. Gur-Dedeoglu, O. Konu, B. Bozkurt, G. Ergul, S. Seckin, and I.G. Yulug, Identification of endogenous reference genes for qRT-PCR analysis in normal matched breast tumor tissues, Oncol. Res., 17 (2009) 353-365.
8. D.S. Chandrashekar et al., UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses, Neoplasia, 19 (2017) 649-658.
9. B. Györffy et al., An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients, Breast Cancer Res. Treat., 123 (2010) 725-731.
10. S.A. Forbes et al., COSMIC: somatic cancer genetics at highresolution, Nucleic Acids Res., 45 (2017) 777-783.
11. Z. Xiong and P. W. Laird, COBRA: a sensitive and quantitative DNA methylation assay, Nucleic Acids Res., 25 (1997) 2532- 2534.
12. L.M. Heiser, A. Sadanandam, W.L. Kuo et al., Subtype and pathway specific responses to anticancer compounds in breast cancer, Pro Natl Aca Sc USA, 109 (2012) 2724-2729.
13. R. Dreos, G. Ambrosini, R.C. Périer, and P. Bucher, The Eukaryotic Promoter Database: expansion of EPDnew and new promoter analysis tools, Nucleic Acids Res., 43 (2015) 92-96.
14. W.J. Kent et al., The Human Genome Browser at UCSC, Genome Res., 12 (2002) 996-1006.
15. D.L. Holliday, V. Speirs, Choosing the right cell line for breast cancer research, Breast Cancer Res., 13 (2011) 215.
16. K.J. Chavez, S.V. Garimella, S. Lipkowitz, Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer, Breast Dis., 32 (2010) 35-48.